Oral Proteins & Peptides Market by Molecule (Semaglutide, Linaclotide, Calcitonin), Drug Class (GLP-1 Receptor Agonist, GEP, CGRP), Therapeutic Area (Diabetes, Gastroenterology, Genetic Disorder), Formulation (Tablet, Capsule) - Global Forecast to 2030
세계 경구 단백질 및 펩티드 시장 규모는 2025년 88억 5,000만 달러에서 2030년까지 240억 달러에 달할 것으로 예상되며, 2025-2030년의 예측 기간 동안 연평균 22.1% 성장할 것으로 예측됩니다.
| 조사 범위 |
| 조사 대상 연도 |
2024-2030년 |
| 기준 연도 |
2024년 |
| 예측 기간 |
2024-2030년 |
| 단위 |
10억 달러 |
| 부문 |
분자, 약품 유형, 치료 영역, 제형, 최종 사용자 |
| 대상 지역 |
북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카 |
경구용 펩티드, 특히 당뇨병 및 중추신경계(CNS) 질환과 같은 만성 질환 치료에 사용되는 경구용 펩티드에 대한 수요 증가가 시장 성장을 가속하는 주요 요인으로 작용하고 있습니다. 또한, 주요 기업들의 R&D 투자 증가는 혁신적인 경구용 펩티드의 개발 및 출시로 이어지고 있습니다. 약물 전달 기술의 지속적인 발전도 시장 확대에 기여하고 있습니다.
그러나 시장은 높은 개발 비용과 제형 및 안정성 관련 장애물 등의 문제에 직면해 있으며, 이는 성장의 걸림돌로 작용하고 있습니다.
"분자별로는 세마글루티드 분자가 2024년 가장 큰 점유율을 차지했습니다."
세마글루티드는 글루카곤 유사 펩티드-1(GLP-1)의 유사체로 혈당 및 식욕 조절에 중요한 역할을 하는 호르몬으로 2형 당뇨병 및 비만 치료에 사용됩니다. 세마글루티드는 혈당 상승에 따른 인슐린 분비를 촉진하고, 혈당을 상승시키는 글루카곤의 분비를 억제하며, 식후 포만감을 촉진하여 식사량을 감소시키는 작용을 합니다.
RYBELSUS로 출시된 경구용 세마글루티드는 미국 FDA에서 2형 당뇨병 치료제로 승인된 최초의 경구용 GLP-1 수용체 작용제입니다. GLP-1 수용체 작용제 계열은 2형 당뇨병 관리에 널리 사용되고 권장되는 약물입니다.
"미국은 예측 기간 동안 경구 단백질 및 펩티드 시장을 계속 독점할 것으로 예측됩니다."
미국은 세계 최대의 바이오의약품 시장이자 바이오의약품 연구 및 투자의 선두주자입니다. 이러한 성장은 감염성 질환 환자 증가, 바이오 의약품의 중요성 증가, 의료 부문의 안전하고 우수한 품질의 제품에 대한 수요 등 여러 요인에 기인합니다. 제약회사 및 바이오테크놀러지 기업뿐만 아니라 정부 기관에서도 생물의학 연구에 대한 투자와 자금 지원이 크게 증가하고 있습니다.
또한, Novo Nordisk A/S(덴마크), AbbVie, Inc.(미국), Pfizer Inc.(미국) 등 여러 주요 시장 기업의 존재도 시장 성장에 중요한 역할을 하고 있습니다. 중요한 성장 요인으로 작용하고 있습니다.
세계의 경구 단백질 및 펩티드 시장에 대해 조사 분석했으며, 주요 촉진요인과 억제요인, 경쟁 구도, 향후 동향 등의 정보를 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 주요 조사 결과
- 경구 단백질 및 펩티드 시장 개요
- 북미 경구 단백질 및 펩티드 시장 점유율 : 제형별, 국가별(2024년)
- 경구 단백질 및 펩티드 시장 점유율 : 치료 영역별(2024년)
- 경구 단백질 및 펩티드 시장 점유율 : 최종사용자별(2025년·2030년)
- 경구 단백질 및 펩티드 시장 : 지역 목표 성장 기회
제5장 시장 개요
- 서론
- 시장 역학
- 생태계 분석
- 원재료 벤더의 역할
- 제품 프로바이더의 역할
- 최종사용자의 역할
- 규제기관의 역할
- 밸류체인 분석
- 공급망 분석
- Porter의 Five Forces 분석
- 주요 이해관계자와 구입 기준
- 가격 분석
- 평균 판매 가격 : 주요 기업별
- 평균 판매 가격 : 국가/지역별
- 규제 상황
- 규제 시나리오
- 규제기관, 정부기관, 기타 조직
- 고객의 비즈니스에 영향을 미치는 동향/혼란
- 기술 분석
- 파이프라인 분석
- 특허 분석
- 조사 방법
- 특허 출원과 취득 건수(2014년-2025년)
- 상환 시나리오
- 주요 컨퍼런스 및 이벤트(2025년-2026년)
- 투자 및 자금조달 시나리오
- 경구 단백질 및 펩티드 시장 AI의 영향
- 2025년 미국 관세의 영향 - 경구 단백질 및 펩티드 시장
- 서론
- 주요 관세율
- 가격 영향 분석
- 국가/지역에 대한 영향
- 제조에 대한 영향
- 제조업체에 대한 제안
제6장 경구 단백질 및 펩티드 시장 : 분자별
- 서론
- SEMAGLUTIDE
- CALCITONIN
- LINACLOTIDE
- TROFINETIDE드
- VOCLOSPORIN
- PLECANATIDE
- 기타 분자
제7장 경구 단백질 및 펩티드 시장 : 약제 클래스별
- 서론
- 글루카곤 유사 펩티드-1 수용체 작용제
- 칼시토닌 유전자 관련 펩티드 수용체 길항제
- 구아닐레이트 사이클라제 C 작용제
- 글리신 프롤린 글루타메이트
- 칼시뉴린 억제제 면역 억제약
- 기타 약제 클래스
제8장 경구 단백질 및 펩티드 시장 : 제형별
제9장 경구 단백질 및 펩티드 시장 : 치료 영역별
- 서론
- 당뇨병
- 중추신경계 질환
- 소화기내과
- 유전성 질환
- 신장
- 비만 및 과체중
- 기타 치료 영역
제10장 경구 단백질 및 펩티드 시장 : 최종사용자별
- 서론
- 재택치료
- 장기 케어 시설
- 병원 및 전문 클리닉
제11장 경구 단백질 및 펩티드 시장 : 지역별
- 서론
- 북미
- 유럽
- 유럽의 거시경제 전망
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 네덜란드
- 기타 유럽
- 아시아태평양
- 아시아태평양의 거시경제 전망
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
- 라틴아메리카
- 라틴아메리카의 거시경제 전망
- 브라질
- 멕시코
- 기타 라틴아메리카
- 중동
- 아프리카
제12장 경쟁 구도
- 개요
- 주요 시장 진출기업의 전략/강점
- 매출 분석(2022년-2024년)
- 시장 점유율 분석(2024년)
- 기업 평가 매트릭스
- 기업 평가 매트릭스 : 스타트업/중소기업(2024년)
- 평가와 재무 지표
- 브랜드/제품 비교
- 경쟁 시나리오
제13장 기업 개요
- 서론
- 주요 기업
- NOVO NORDISK A/S
- ABBVIE INC.
- PFIZER INC.
- BAUSCH HEALTH COMPANIES INC.
- CHIESI FARMACEUTICI S.P.A.
- ACADIA PHARMACEUTICALS INC.
- AURINIA PHARMACEUTICALS INC.
- MERCK & CO., INC.
- JOHNSON & JOHNSON SERVICES, INC.
- SWK HOLDINGS
- R-PHARM JSC
- ENTERA BIO LTD.
- PROXIMA CONCEPTS
- 기타 기업
- ASTRAZENECA PLC
- REGOR THERAPEUTICS GROUP
- TERNS PHARMACEUTICALS, INC.
- STRUCTURE THERAPEUTICS
- VIKING THERAPEUTICS
- PROTAGONIST THERAPEUTICS INC.
- RANI THERAPEUTICS
- CARMOT THERAPEUTICS, INC.
- ZEALAND PHARMA
- SCIWIND BIOSCIENCES CO., LTD.
- JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
제14장 부록
LSH
The global market for oral proteins and peptides is projected to reach USD 24.00 billion by 2030 from USD 8.85 billion in 2025, at a CAGR of 22.1% during the forecast period from 2025 to 2030.
| Scope of the Report |
|---|
| Years Considered for the Study | 2024-2030 |
| Base Year | 2024 |
| Forecast Period | 2024-2030 |
| Units Considered | Value (USD billion) |
| Segments | Molecule, Drug Class, Therapeutic Area, Formulation, and End User |
| Regions covered | North America, Europe, Asia Pacific, Latin America, Middle East, and Africa |
The increase in demand for oral peptides, particularly for the treatment of chronic diseases such as diabetes and central nervous system (CNS) disorders, is a major driver of growth in this market. Additionally, rising investments in research and development by key players are leading to the creation and launch of innovative oral peptides. Continuous advancements in drug delivery technologies are also contributing to market expansion.
However, the market faces challenges, including high development costs and obstacles related to formulation and stability, which hinder growth.
"The semaglutide molecule segment accounted for the largest share of the market, by molecule, in 2024."
In 2024, the semaglutide segment held the largest share of the global oral proteins and peptides market. Semaglutide is an analog of glucagon-like peptide-1 (GLP-1), a hormone that plays a key role in regulating blood sugar levels and appetite. It is used to manage type 2 diabetes and obesity. Semaglutide functions by enhancing insulin secretion in response to elevated blood glucose levels, reducing glucagon release (which normally raises blood sugar), and promoting a feeling of fullness after eating, thereby helping to reduce food intake.
Oral semaglutide, marketed as RYBELSUS, is the first oral GLP-1 receptor agonist approved by the US FDA for the treatment of type 2 diabetes. As a class, GLP-1 receptor agonists are widely utilized and recommended for managing type 2 diabetes.
"The US will continue to dominate the oral proteins and peptides market during the forecast period."
The US is the largest biopharmaceutical market in the world and a leader in biopharmaceutical research and investments. This growth is driven by several factors, including the increasing patient population suffering from infectious diseases, the rising importance of biopharmaceuticals, and the need for safe, high-quality products in the healthcare sector. There has been a significant increase in investments and funding for biomedical research from government agencies as well as pharmaceutical and biotechnology companies.
Furthermore, the early adoption of emerging technologies and alternative therapies and the widespread availability of oral proteins and peptides in the region support market expansion. The strong presence of several key market players, including Novo Nordisk A/S (Denmark), AbbVie, Inc. (US), and Pfizer Inc. (US), is another crucial factor contributing to this growth.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and Middle East & Africa (5%)
List of Key Companies Profiled in the Report:
Novo Nordisk A/S (Denmark), AbbVie Inc. (US), Pfizer Inc. (US), Acadia Pharmaceuticals Inc. (US), Aurinia Pharmaceuticals Inc. (Canada), Bausch Health Companies Inc. (Canada), CHIESI Farmaceutici S.p.A. (Italy), EnteraBio Ltd. (Israel), Merck & Co., Inc. (US), Johnson & Johnson Services, Inc. (US), R-Pharm JSC (Russia), Proxima Concepts (US), and SWK Holdings Corporation (US)
Research Coverage:
This research report categorizes the oral proteins and peptides market by molecule (trofinetide, semaglutide, linaclotide, voclosporin, plecanatide, calcitonin, and other drugs), drug class (analog of glycine-proline-glutamate (GPE), glucagon-like peptide-1 (GLP-1) receptor agonists, guanylate cyclase-C agonists, calcineurin-inhibitor immunosuppressants, calcitonin gene-related peptide (CGRP) receptor antagonists, and other drugs), therapeutic area (genetic disorders, diabetes, nephrology, gastroenterology, CNS disorders, obesity & overweight, and other therapeutic areas), formulation (tablets, capsules, and oral solutions), end user (home care settings, long-term care facilities, and hospitals & specialty clinics), and region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the oral proteins and peptides market. A comprehensive analysis of key industry players has been conducted to provide insights into their business overview, products, solutions, strategies, collaborations, partnerships, agreements, new launches, acquisitions, and recent developments associated with the oral proteins and peptides market.
Key Benefits of Buying the Report:
The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the oral proteins and peptides market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
- Analysis of key drivers (rising prevalence of chronic diseases such as diabetes, gastroenterology diseases, and kidney diseases; advancements in drug delivery technologies; patient preference and compliance for oral route of drug administration; and increasing adoption of inorganic growth strategies such as collaborations and agreements), restraints (high cost associated with drug development, contraindication of oral proteins and peptides, and stringent regulatory approval process), opportunities (robust clinical trial pipeline for oral proteins and peptides and growing demand for non-invasive and patient-friendly treatment options), and Challenges (hurdles in formulation and stability and availability of alternative therapies) influencing the growth of the market.
- Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the oral proteins and peptides market.
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the oral proteins and peptides market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the oral proteins and peptides market.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 MARKET SCOPE
- 1.3.1 MARKETS AND REGIONS COVERED
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
- 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS
- 1.5 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 RESEARCH DESIGN
- 2.1.2 SECONDARY DATA
- 2.1.3 PRIMARY DATA
- 2.2 MARKET SIZE ESTIMATION
- 2.2.1 INSIGHTS FROM PRIMARIES
- 2.2.2 MARKET SIZE ASSESSMENT AT SEGMENT LEVEL
- 2.3 MARKET GROWTH FORECAST
- 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 ORAL PROTEINS & PEPTIDES MARKET OVERVIEW
- 4.2 NORTH AMERICA: ORAL PROTEINS & PEPTIDES MARKET SHARE, BY FORMULATION AND COUNTRY (2024)
- 4.3 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY THERAPEUTIC AREA, 2024
- 4.4 ORAL PROTEINS & PEPTIDES MARKET SHARE, BY END USER, 2025 VS. 2030
- 4.5 ORAL PROTEINS & PEPTIDES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Increasing burden of chronic diseases
- 5.2.1.2 Advancements in drug delivery technologies
- 5.2.1.3 Higher patient compliance and preference for oral route
- 5.2.1.4 Expanding therapeutic applications of oral proteins & peptides
- 5.2.2 RESTRAINTS
- 5.2.2.1 High cost of drug development
- 5.2.2.2 Contraindication of oral proteins & peptides
- 5.2.2.3 Stringent regulatory approval process
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Robust clinical trial pipeline for oral proteins & peptides
- 5.2.3.2 Growing demand for personalized medicine
- 5.2.4 CHALLENGES
- 5.2.4.1 Hurdles in formulation and stability
- 5.2.4.2 Availability of alternative therapies
- 5.3 ECOSYSTEM ANALYSIS
- 5.3.1 ROLE OF RAW MATERIAL VENDORS
- 5.3.2 ROLE OF PRODUCT PROVIDERS
- 5.3.3 ROLE OF END USERS
- 5.3.4 ROLE OF REGULATORY AUTHORITIES
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 SUPPLY CHAIN ANALYSIS
- 5.6 PORTER'S FIVE FORCES ANALYSIS
- 5.6.1 THREAT OF NEW ENTRANTS
- 5.6.2 THREAT OF SUBSTITUTES
- 5.6.3 BARGAINING POWER OF SUPPLIERS
- 5.6.4 BARGAINING POWER OF BUYERS
- 5.6.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.7 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.7.1 KEY STAKEHOLDERS
- 5.7.2 BUYING CRITERIA
- 5.8 PRICING ANALYSIS
- 5.8.1 AVERAGE SELLING PRICE, BY KEY PLAYER
- 5.8.2 AVERAGE SELLING PRICE, BY COUNTRY & REGION
- 5.9 REGULATORY LANDSCAPE
- 5.9.1 REGULATORY SCENARIO
- 5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.10 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
- 5.11 TECHNOLOGY ANALYSIS
- 5.11.1 KEY TECHNOLOGIES
- 5.11.1.1 Transient permeation enhancers
- 5.11.1.2 Gastrointestinal permeation enhancement technology
- 5.11.1.3 Oral sCT (OSTORA) technology
- 5.11.2 COMPLEMENTARY TECHNOLOGIES
- 5.11.2.1 Peptelligence
- 5.11.2.2 ThioMatrix
- 5.11.2.3 Transferrin-based recombinant fusion proteins
- 5.11.3 ADJACENT TECHNOLOGIES
- 5.11.3.1 Oramed and Orasome
- 5.11.3.2 Q-sphera
- 5.11.3.3 Nanoinclusion
- 5.11.3.4 Oleotec and Soctec
- 5.12 PIPELINE ANALYSIS
- 5.13 PATENT ANALYSIS
- 5.13.1 METHODOLOGY
- 5.13.2 PATENTS APPLIED AND GRANTED, 2014-2025
- 5.14 REIMBURSEMENT SCENARIO
- 5.15 KEY CONFERENCES & EVENTS, 2025-2026
- 5.16 INVESTMENT & FUNDING SCENARIO
- 5.17 IMPACT OF AI ON ORAL PROTEINS & PEPTIDES MARKET
- 5.18 IMPACT OF 2025 US TARIFFS-ORAL PROTEINS & PEPTIDES MARKET
- 5.18.1 INTRODUCTION
- 5.18.2 KEY TARIFF RATES
- 5.18.3 PRICE IMPACT ANALYSIS
- 5.18.4 IMPACT ON COUNTRIES/REGIONS
- 5.18.4.1 US
- 5.18.4.2 Europe
- 5.18.4.3 Asia Pacific
- 5.18.5 IMPACT ON MANUFACTURING INDUSTRIES
- 5.18.6 RECOMMENDATIONS FOR MANUFACTURERS
6 ORAL PROTEINS & PEPTIDES MARKET, BY MOLECULE
- 6.1 INTRODUCTION
- 6.2 SEMAGLUTIDE
- 6.2.1 INCREASED PATIENT COMPLIANCE TO BOOST MARKET GROWTH
- 6.3 CALCITONIN
- 6.3.1 NEED FOR EFFECTIVE ANTI-MIGRAINE DRUGS TO SUPPORT ADOPTION
- 6.4 LINACLOTIDE
- 6.4.1 RISING PREVALENCE OF GASTRIC DISORDERS TO SUPPORT GROWTH
- 6.5 TROFINETIDE
- 6.5.1 FDA APPROVAL TO DRIVE MARKET
- 6.6 VOCLOSPORIN
- 6.6.1 INCREASING REGULATORY APPROVALS TO DRIVE PATIENT ACCESS AND ADOPTION
- 6.7 PLECANATIDE
- 6.7.1 INCREASED PATIENT CONVENIENCE TO SUPPORT GROWTH
- 6.8 OTHER MOLECULES
7 ORAL PROTEINS & PEPTIDES MARKET, BY DRUG CLASS
- 7.1 INTRODUCTION
- 7.2 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS
- 7.2.1 INCREASING ADOPTION TO SUPPORT GROWTH
- 7.3 CALCITONIN GENE-RELATED PEPTIDE RECEPTOR ANTAGONISTS
- 7.3.1 INCREASING PREVALENCE OF MIGRAINE TO DRIVE ADOPTION
- 7.4 GUANYLATE CYCLASE-C AGONISTS
- 7.4.1 RISING PREVALENCE OF IBS AND CIC TO DRIVE MARKET
- 7.5 GLYCINE-PROLINE-GLUTAMATE
- 7.5.1 FOCUS ON DEVELOPING GPE-CLASS DRUGS TO SUPPORT GROWTH
- 7.6 CALCINEURIN-INHIBITOR IMMUNOSUPPRESSANTS
- 7.6.1 INCREASING NUMBER OF ORGAN TRANSPLANTS TO PROMOTE GROWTH
- 7.7 OTHER DRUG CLASSES
8 ORAL PROTEINS & PEPTIDES MARKET, BY FORMULATION
- 8.1 INTRODUCTION
- 8.2 TABLETS
- 8.2.1 HIGH ADOPTION AND EASE OF ADMINISTRATION TO SUPPORT GROWTH
- 8.3 CAPSULES
- 8.3.1 RISING DEMAND FOR ORAL BIOLOGICS AND INCREASED PATIENT COMPLIANCE TO DRIVE MARKET
- 8.4 ORAL SOLUTIONS
- 8.4.1 GROWING FOCUS ON IMPROVING BIOAVAILABILITY AND PATIENT CONVENIENCE TO SUPPORT MARKET GROWTH
9 ORAL PROTEINS & PEPTIDES MARKET, BY THERAPEUTIC AREA
- 9.1 INTRODUCTION
- 9.2 DIABETES
- 9.2.1 HIGH EFFICACY TO SUPPORT END-USER ADOPTION
- 9.3 CNS DISORDERS
- 9.3.1 GROWING BURDEN OF NEUROLOGICAL DISORDERS TO PROPEL MARKET
- 9.4 GASTROENTEROLOGY
- 9.4.1 RISING PREVALENCE OF GASTROINTESTINAL DISORDERS TO SUPPORT SEGMENT GROWTH
- 9.5 GENETIC DISORDERS
- 9.5.1 GROWING PREVALENCE OF GENETIC DISORDERS TO SUPPORT GROWTH
- 9.6 NEPHROLOGY
- 9.6.1 RISING PREVALENCE OF KIDNEY DISORDERS IN GERIATRIC POPULATION TO PROPEL MARKET
- 9.7 OBESITY & OVERWEIGHT
- 9.7.1 RISING INCIDENCE OF OBESITY TO PROPEL MARKET GROWTH
- 9.8 OTHER THERAPEUTIC AREAS
10 ORAL PROTEINS & PEPTIDES MARKET, BY END USER
- 10.1 INTRODUCTION
- 10.2 HOME CARE SETTINGS
- 10.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
- 10.3 LONG-TERM CARE FACILITIES
- 10.3.1 RISING GERIATRIC POPULATION AND PREVALENCE OF CHRONIC DISEASES TO SUPPORT GROWTH
- 10.4 HOSPITALS & SPECIALTY CLINICS
- 10.4.1 ADOPTION OF ORAL PEPTIDES FOR VARIED INDICATIONS TO DRIVE MARKET
11 ORAL PROTEINS & PEPTIDES MARKET, BY REGION
- 11.1 INTRODUCTION
- 11.2 NORTH AMERICA
- 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 11.2.2 US
- 11.2.2.1 US to hold large shares in North American and global markets
- 11.2.3 CANADA
- 11.2.3.1 Increasing prevalence of obesity and heart failure to support market growth
- 11.3 EUROPE
- 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 11.3.2 GERMANY
- 11.3.2.1 Germany to hold largest share of European market
- 11.3.3 UK
- 11.3.3.1 Strong focus on advancement of life sciences to support market growth
- 11.3.4 FRANCE
- 11.3.4.1 Growing prevalence of diabetes and government initiatives to boost market growth
- 11.3.5 ITALY
- 11.3.5.1 Presence of major pharmaceutical and biotechnology companies to drive market
- 11.3.6 SPAIN
- 11.3.6.1 Initiatives associated with GLP-1 drugs to drive market
- 11.3.7 NETHERLANDS
- 11.3.7.1 Rising awareness and focus on pharmaceutical R&D to support market growth
- 11.3.8 REST OF EUROPE
- 11.4 ASIA PACIFIC
- 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 11.4.2 CHINA
- 11.4.2.1 Increasing R&D expenditure to drive market
- 11.4.3 JAPAN
- 11.4.3.1 Increasing prevalence of diabetes to drive market
- 11.4.4 INDIA
- 11.4.4.1 Strong initiatives to develop cost-effective and patient-friendly medications to aid market growth
- 11.4.5 AUSTRALIA
- 11.4.5.1 Rising access to GLP-1 drugs and government support to drive market
- 11.4.6 SOUTH KOREA
- 11.4.6.1 Growing focus on development of innovative treatment solutions to propel market growth
- 11.4.7 REST OF ASIA PACIFIC
- 11.5 LATIN AMERICA
- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 11.5.2 BRAZIL
- 11.5.2.1 Brazil to hold largest market share in Latin America
- 11.5.3 MEXICO
- 11.5.3.1 Growing diabetes and obesity cases to drive market
- 11.5.4 REST OF LATIN AMERICA
- 11.6 MIDDLE EAST
- 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
- 11.6.2 GCC COUNTRIES
- 11.6.2.1 Saudi Arabia
- 11.6.2.1.1 Growing availability of GLP-1 drugs to support market growth
- 11.6.2.2 UAE
- 11.6.2.2.1 Regulatory approvals for GLP-1 drugs to propel market
- 11.6.2.3 Rest of GCC countries
- 11.6.3 REST OF MIDDLE EAST
- 11.7 AFRICA
- 11.7.1 LARGE AND GROWING PATIENT POPULATION AND FAVORABLE HEALTHCARE REFORMS TO DRIVE MARKET
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA
12 COMPETITIVE LANDSCAPE
- 12.1 OVERVIEW
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ORAL PROTEINS & PEPTIDES MARKET
- 12.3 REVENUE ANALYSIS, 2022-2024
- 12.4 MARKET SHARE ANALYSIS, 2024
- 12.5 COMPANY EVALUATION MATRIX
- 12.5.1 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
- 12.5.1.1 Stars
- 12.5.1.2 Emerging leaders
- 12.5.1.3 Pervasive players
- 12.5.1.4 Participants
- 12.5.2 COMPANY EVALUATION MATRIX: PLAYERS WITH PRODUCTS IN PIPELINE, 2024
- 12.5.2.1 Stars
- 12.5.2.2 Emerging leaders
- 12.5.2.3 Pervasive players
- 12.5.2.4 Participants
- 12.5.3 COMPANY FOOTPRINT: KEY PLAYERS, 2024
- 12.5.3.1 Company footprint
- 12.5.3.2 Region footprint
- 12.5.3.3 Molecule footprint
- 12.5.3.4 Formulation footprint
- 12.5.3.5 Therapeutic area footprint
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
- 12.6.1 PROGRESSIVE COMPANIES
- 12.6.2 RESPONSIVE COMPANIES
- 12.6.3 DYNAMIC COMPANIES
- 12.6.4 STARTING BLOCKS
- 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
- 12.6.5.1 Detailed list of key startups/SMEs
- 12.6.5.2 Competitive benchmarking of key startups/SMEs
- 12.7 VALUATION & FINANCIAL METRICS
- 12.7.1 FINANCIAL METRICS
- 12.7.2 COMPANY VALUATION
- 12.8 BRAND/PRODUCT COMPARISON
- 12.9 COMPETITIVE SCENARIO
- 12.9.1 PRODUCT APPROVALS
- 12.9.2 DEALS
- 12.9.3 EXPANSIONS
- 12.9.4 OTHER DEVELOPMENTS
13 COMPANY PROFILES
- 13.1 INTRODUCTION
- 13.2 KEY PLAYERS
- 13.2.1 NOVO NORDISK A/S
- 13.2.1.1 Business overview
- 13.2.1.2 Products offered
- 13.2.1.3 Recent developments
- 13.2.1.3.1 Product launches & approvals
- 13.2.1.3.2 Deals
- 13.2.1.3.3 Expansions
- 13.2.1.3.4 Other developments
- 13.2.1.4 MnM view
- 13.2.1.4.1 Right to win
- 13.2.1.4.2 Strategic choices
- 13.2.1.4.3 Weaknesses & competitive threats
- 13.2.2 ABBVIE INC.
- 13.2.2.1 Business overview
- 13.2.2.2 Products offered
- 13.2.2.3 Recent developments
- 13.2.2.3.1 Product approvals
- 13.2.2.3.2 Deals
- 13.2.2.4 MnM view
- 13.2.2.4.1 Right to win
- 13.2.2.4.2 Strategic choices
- 13.2.2.4.3 Weaknesses & competitive threats
- 13.2.3 PFIZER INC.
- 13.2.3.1 Business overview
- 13.2.3.2 Product pipeline
- 13.2.3.3 Recent developments
- 13.2.3.3.1 Product approvals
- 13.2.3.3.2 Deals
- 13.2.3.3.3 Other developments
- 13.2.3.4 MnM view
- 13.2.3.4.1 Right to win
- 13.2.3.4.2 Strategic choices
- 13.2.3.4.3 Weaknesses & competitive threats
- 13.2.4 BAUSCH HEALTH COMPANIES INC.
- 13.2.4.1 Business overview
- 13.2.4.2 Products offered
- 13.2.4.3 Recent developments
- 13.2.4.3.1 Product approvals
- 13.2.5 CHIESI FARMACEUTICI S.P.A.
- 13.2.5.1 Business overview
- 13.2.5.2 Products offered
- 13.2.5.3 Recent developments
- 13.2.6 ACADIA PHARMACEUTICALS INC.
- 13.2.6.1 Business overview
- 13.2.6.2 Products offered
- 13.2.6.3 Recent developments
- 13.2.6.3.1 Product approvals
- 13.2.7 AURINIA PHARMACEUTICALS INC.
- 13.2.7.1 Business overview
- 13.2.7.2 Products offered
- 13.2.7.3 Recent developments
- 13.2.7.3.1 Product approvals
- 13.2.8 MERCK & CO., INC.
- 13.2.8.1 Business overview
- 13.2.8.2 Product pipeline
- 13.2.8.3 Recent developments
- 13.2.8.3.1 Deals
- 13.2.8.3.2 Other developments
- 13.2.9 JOHNSON & JOHNSON SERVICES, INC.
- 13.2.9.1 Business overview
- 13.2.9.2 Product pipeline
- 13.2.9.3 Recent developments
- 13.2.9.3.1 Other developments
- 13.2.10 SWK HOLDINGS
- 13.2.10.1 Business overview
- 13.2.10.2 Product pipeline
- 13.2.10.3 Recent developments
- 13.2.10.3.1 Other developments
- 13.2.11 R-PHARM JSC
- 13.2.11.1 Business overview
- 13.2.11.2 Products in pipeline
- 13.2.12 ENTERA BIO LTD.
- 13.2.12.1 Business overview
- 13.2.12.2 Product pipeline
- 13.2.12.3 Recent developments
- 13.2.12.3.1 Deals
- 13.2.12.3.2 Other developments
- 13.2.13 PROXIMA CONCEPTS
- 13.2.13.1 Business overview
- 13.2.13.2 Products in pipeline
- 13.3 OTHER PLAYERS
- 13.3.1 ASTRAZENECA PLC
- 13.3.2 REGOR THERAPEUTICS GROUP
- 13.3.3 TERNS PHARMACEUTICALS, INC.
- 13.3.4 STRUCTURE THERAPEUTICS
- 13.3.5 VIKING THERAPEUTICS
- 13.3.6 PROTAGONIST THERAPEUTICS INC.
- 13.3.7 RANI THERAPEUTICS
- 13.3.8 CARMOT THERAPEUTICS, INC.
- 13.3.9 ZEALAND PHARMA
- 13.3.10 SCIWIND BIOSCIENCES CO., LTD.
- 13.3.11 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
14 APPENDIX
- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS
